June 28, 2021 7:52am

And records need to be broken as a matter of course or was it cause?

News: Intellia Therapeutics (NTLA +$32.25 or +41.29% pre-market indication) on Saturday, NTLA released interim data from the P1 trial of its collaboration with Regeneron (RGEN) on an experimental therapy for transthyretin amyloidosis (ATTR) – a protein misfolding disorder.

Pre-open indications: 5 BUYs: EDIT, CRSP, NTLA, VCEL, PSTI; 1 SELL: GBT; 2 Maintain SELL: BSTG, CLLS

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming in July, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are DOWN -0.1206% (-1 points), S&P futures are UP +0.09% (+ point) and NASDAQ futures are UP +0.30% (+43 points)

 

U.S. stock indexes were mixed Monday morning after the S&P 500 notched its best week since February, as well as a new record, on Friday,

European markets slid as Covid cases weigh on sentiment,

Asia-Pacific markets were mixed after official data showed that China’s industrial profits for May slowed.

 

Henry’omics:

Stocks posted their best week in months on Friday as investors are growing more confident the current inflation in the U.S. is not a sustained economic threat, but a temporary uptick.

The Nasdaq erased earlier gains and closed 0.1% lower at 14,360.39 amid a rise in bond yields.

As Friday saw heightened trading volume as FTSE Russell was set to rebalance its U.S. stock indexes at the market close.

While for the week: the S&P 500 rallied 2.7%, the Dow gained 3.4% and the Nasdaq advanced 2.4%.

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results to date …  https://www.regmedinvestors.com/articles/11628

 

Friday’s evening’s recap: “RegMed Investors’ (RMi) closing bell: a good week even with Russell rebalances on a Friday. A volume spurt in Friday’s session, but, ends with a positive close and I am still more right than most” … https://www.regmedinvestors.com/articles/11973

  • The Nasdaq closed DOWN -9.32 points (-0.06%);
  • The IBB closed UP +0.84% and XBI closed up +1.01%
  • Sector volume was HIGH with 17 of the 18-upside having higher than the 3-month average volume with HIGH volume of 8 of 13-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -0.35 points or -2.19% at 15.62
  • Friday’s percentage (%) of the 18-upside were +0.52% (BLFS) to +4.46% (CLBS) while the 13-downside ranges from -0.26% (SLDB) to -7.41% (BSTG);

Q2/21:

June: 14 positive and 6 negative closes

May:  8 positive, 12 negative closes and 1 holiday

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …

Biostage (BSTG) closed down -$0.10 to $1.25 with 1,00 shares traded after Thursday’s +$0.10 to $1.35 with 1,920 shares traded, Wednesday’s -$0.05 to $1.25 with 11,915 shares traded, Tuesday’s +$0.09 to $1.30 with 4,779 shares traded and last Monday’s flat at $1.21 with 572 shares traded. WHAT role is DST Capital “playing” in these on-going “volume-pumping” pricing “moves”?

Question#1: The REAL question to be ANSWERED is WHO is advising them in ALL of these endeavors and was has been the effect and did/has affected conditions within the company and past issues that STILL remain UNRESOLVED?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

SELL:

Global Blood Therapeutics (GBT) closed flat at $36.44 after Thursday’s +$0.76 to $36.44, Wednesday’s $35.68, Tuesday’s $36.02, Monday’s $36.69 and last Friday’s $36.64 and has a negative -$0.47 or -1.29% aftermarket indication.

BUY:

Intellia Therapeutics (NTLA) closed up +$1.99 to $88.83 after Thursday’s +$3.25 to $86.84, Wednesday’s +$4.68 to $83.59, Tuesday’s -$0.31 to $78.91 and last Monday’s +$3.30 to $79.22 and has +$32.25 or +41.29% pre-market indication). On Saturday, NTLA released interim data from the P1 trial of its collaboration with Regeneron (REGN) on an experimental therapy for transthyretin amyloidosis (ATTR) – a protein misfolding disorder. NTLA has risen over 60% this year, to a Friday close of $88.83, with a 52-week change of +335.01%. Take some $ off the table.

Vericel (VCEL) closed up +1.64 to $67.40 after Thursday’s $65.76 and Wednesday’s $64.79 Tuesday’s $61.06 and last Monday’s $61.23 with a positive +2.60 or 3.86% aftermarket (Friday) indication.

Pluristem (PSTI) closed down -$0.06 to $4.02 and has a positive +$0.10 or +2.49% premarket (Friday) indication.

Editas Medicine (EDIT) closed up +$1.01 to $41.88 after Thursday’s +$3.05 to $40.87 Wednesday’s +$0.1.41 to $37.82, Tuesday’s -$0.45 to $36.41 and last Tuesday’s +$0.98 to $36.86 and has a positive +4.61 or +10.55% pre-market indication.

CRISPR Therapeutics (CRSP) closed up +$4.764 to $142.52 after Thursday's +$7.20 to $137.88 after Wednesday’s +$1.48 to $130.48 and has a positive +12.98 or +9.11% pre-market indication.

 

Maintaining SELL:

Cellectis SA (CLLS) closed up +0.13 to $15.62 after Thursday’s $0.69 to $15.49, Wednesday’s +$0.19 to $14.80, Tuesday’s +$0.10 to $14.61 and last Tuesday’s -$0.34 to $14.51 and has a negative -$0.1 or -0.90% pre-market indication.

 

The BOTTOM LINE: Cell and gene therapy sector equities are still flying foster by tailwinds however; headwinds and turbulence are ahead - investors should use rallies to book profits.

Notice the dwindling of upside movement and increasing downside numbers: overpast three (3) sessions …

  • Friday closed positive with 18 advancers, 13 decliners, 3 flat and 1 acquired
  • Thursday closed positive with 28 advancers, 5 decliners, 1 flat and 1 acquired
  • Wednesday positive with 25 advancers, 9 decliners and 1 acquired

Friday’s “numbers with-in the advance/Decline (A/D) line had to be totally redone as the session came to a close as changes in this year’s Russell Index rebalancing were too significant to ignore; although in “our” cell and gene therapy universe, the recalibration of indexes changes did NOT any dramatic shifts in sector composition.

I also continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

A true contrarian thought …

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.